This is a long-term safety and efficacy of lebrikizumab in participants 6 Months to
Study Details
Internal Title:
J2T-MC-KGBJ
PCH IRB Number:
IRB-24-122
Clinical Trials Government Identifier:
NCT05735483
Diagnoses & Treatments:
Atopic Dermatitis, Eczema, Lebrkizumab
Study Type:
Clinical Trial
Eligibility:
6 months to <18yrs with moderate to severe Atopic Dermatitis who completed the KGBI study.
Enrollment Status:
Open
Phase:
III